Janneke Meulenberg
Directeur Général chez ViciniVax BV
Profil
Janneke Meulenberg is currently the Chief Executive Officer at ViciniVax BV and the Managing Director at MeiraGTx Netherlands BV.
She previously worked as a Principal at Amsterdam Molecular Therapeutics (AMT) Holding NV and ID-Lelystad Instituut Voor Dierhouderij en Diergezondheid BV.
She holds a doctorate degree from the University of Amsterdam and an undergraduate degree from the University of Groningen.
Postes actifs de Janneke Meulenberg
| Sociétés | Poste | Début |
|---|---|---|
ViciniVax BV
 ViciniVax BV Pharmaceuticals: OtherHealth Technology ViciniVax BV develops, commercializes, and markets vaccines for the treatment of cancer. It also develops therapies for cervical cancer. The company was founded by Toos Daemen, Hans Nijman, Alfred N. Nijkerk, Ate van der Zee, and Jan C. Wilschut in 2008 and is headquartered in Groningen, Netherlands. | Directeur Général | - |
MeiraGTx Netherlands BV
 MeiraGTx Netherlands BV Pharmaceuticals: MajorHealth Technology MeiraGTx Netherlands BV operates as a biopharmaceutical company developing local gene therapy for inflammatory diseases. It is into develop adeno-associated viral mediated gene therapy for patients with rheumatic conditions. The company was founded in 2005 and is headquartered in Amsterdam, the Netherlands. | Directeur Général | 01/11/2019 |
Anciens postes connus de Janneke Meulenberg
| Sociétés | Poste | Fin |
|---|---|---|
ID-Lelystad Instituut Voor Dierhouderij En Diergezondheid BV
 ID-Lelystad Instituut Voor Dierhouderij En Diergezondheid BV Miscellaneous Commercial ServicesCommercial Services ID-Lelystad Instituut Voor Dierhouderij En Diergezondheid BV is a Dutch company that engages in research and development on livestock. The private company is based in Lelystad, Netherlands. | Corporate Officer/Principal | - |
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Corporate Officer/Principal | - |
Formation de Janneke Meulenberg
| University of Groningen | Undergraduate Degree |
| University of Amsterdam | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Commercial Services |
ID-Lelystad Instituut Voor Dierhouderij En Diergezondheid BV
ID-Lelystad Instituut Voor Dierhouderij En Diergezondheid BV Miscellaneous Commercial ServicesCommercial Services ID-Lelystad Instituut Voor Dierhouderij En Diergezondheid BV is a Dutch company that engages in research and development on livestock. The private company is based in Lelystad, Netherlands. | Commercial Services |
ViciniVax BV
ViciniVax BV Pharmaceuticals: OtherHealth Technology ViciniVax BV develops, commercializes, and markets vaccines for the treatment of cancer. It also develops therapies for cervical cancer. The company was founded by Toos Daemen, Hans Nijman, Alfred N. Nijkerk, Ate van der Zee, and Jan C. Wilschut in 2008 and is headquartered in Groningen, Netherlands. | Health Technology |
MeiraGTx Netherlands BV
MeiraGTx Netherlands BV Pharmaceuticals: MajorHealth Technology MeiraGTx Netherlands BV operates as a biopharmaceutical company developing local gene therapy for inflammatory diseases. It is into develop adeno-associated viral mediated gene therapy for patients with rheumatic conditions. The company was founded in 2005 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
